English Journal

Severe hypernatremia and hyperchloremia in an elderly patient with IgG-kappa-type multiple myeloma.

Imashuku S, Kudo N, Kubo K.SourceDivision of Hematology, Takasago-seibu Hospital, Takasago, Japan.
Journal of blood medicine.J Blood Med.2013 May 14;4:43-7. doi: 10.2147/JBM.S44091. Print 2013.
A 77-year-old male was admitted to hospital after suffering a pelvic bone fracture in a road traffic accident and was incidentally found to have IgG-kappa-type multiple myeloma with hypercalcemia. The patient was also noted to be hypokalemic and had low HCO3 (-), with possible damage to the distal t
PMID 23700375

The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.

Zhang L, Li L, Yang M, Xu K, Boden G, Yang G.SourceDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, 400010 Chongqing, China.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.Osteoporos Int.2013 Mar;24(3):1107-12. doi: 10.1007/s00198-012-1956-3. Epub 2012 Mar 15.
The secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin, plays an important role in osteoblast formation, maturation, and survival. Here, we report the effects of recombinant human parathyroid hormone (1-34) [rhPTH (1-34)], a bone formation-stimulating agent, and elcatoni
PMID 22419369

Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.

Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC.SourceDepartment of Endocrinology, Tongji Hospital of Tongji University, Shanghai 200065, China.
Chinese medical journal.Chin Med J (Engl).2013 Feb;126(3):457-63.
BACKGROUND: Recombinant human parathyroid hormone (1-34) (rhPTH (1-34)) is the first agent in a unique class of anabolic therapies acting on the skeleton. The efficacy and safety of long-term administration of rhPTH (1-34) in Chinese postmenopausal women had not been evaluated. This study compared t
PMID 23422107